Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. reports news on its clinical-stage biopharmaceutical development of Haduvio, an oral extended-release formulation of nalbuphine, for chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Company updates commonly cover clinical trial results and plans, FDA interactions, medical-conference presentations, intellectual property, and the investigational status of Haduvio.
Trevi also reports financing and corporate updates tied to its development strategy, including common stock offerings, quarterly financial results, cash runway commentary, and participation in healthcare investor events.
Trevi Therapeutics (Nasdaq: TRVI) will present at the Emerging Growth Conference on February 22, 2023, at 10:50 a.m. ET. The presentation will focus on its investigational therapy Haduvio™ (oral nalbuphine ER) targeting chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and prurigo nodularis. Senior leadership, including Jennifer Good, David Clark, and Farrell Simon, will engage in a Q&A session following the presentation. Interested parties can register for the event and access the live webcast on Trevi’s website, with an archived replay available post-event.
Trevi Therapeutics plans to present its investigational therapy Haduvio™ at two major investor conferences in February 2023. The BIO CEO & Investor Conference will take place from February 6-9, with Trevi’s presentation scheduled for February 7 at 10:45 a.m. ET. The SVB Securities Global Biopharma Conference follows from February 13-16, where a presentation is set for February 14 at 11:20 a.m. ET. Trevi Therapeutics, trading under the symbol TRVI, is developing Haduvio for chronic cough and prurigo nodularis, having reported promising Phase 2 trial results for chronic cough in patients with idiopathic pulmonary fibrosis.
Trevi Therapeutics (Nasdaq: TRVI) announced significant business updates on Jan. 5, 2023, highlighting the progression of its investigational therapy, Haduvio™. Aiming to treat chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and prurigo nodularis, Trevi is preparing for several clinical studies in 2023, including a Phase 2 dose-ranging study and a Phase 1b respiratory physiology study. The company is also conducting a human abuse liability study and will request an End-of-Phase 2 meeting with the FDA. Trevi will participate in key conferences starting January 9, 2023.
Trevi Therapeutics (Nasdaq: TRVI) will present at the Biotech Showcase 2023 on January 10, 2023, at 3:00 p.m. PT. This event coincides with the 12th Annual LifeSci Partners Corporate Access Event, held from January 9-11, 2023, in San Francisco, CA. Trevi is focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough and prurigo nodularis. Positive results from the Phase 2 CANAL trial for chronic cough related to idiopathic pulmonary fibrosis have prompted Trevi to prioritize further clinical development in this area.
Trevi Therapeutics has appointed David Clark, MD, MRCP, as the new Chief Medical Officer to advance the development of Haduvio™, an oral investigational therapy for chronic cough related to idiopathic pulmonary fibrosis. Dr. Clark brings over 25 years of experience in clinical development and has previously led clinical teams at several biopharmaceutical companies. He will play a critical role in executing Trevi's clinical strategies, supported by the insights from prior CMO Thomas Sciascia, who transitions to Chief Science Officer.
Trevi Therapeutics (TRVI) reported its Q3 2022 financial results, highlighting a net loss of $8.3 million, up from $7.3 million year-over-year, largely due to increased R&D expenses of $5.8 million. The clinical-stage biopharmaceutical firm announced significant progress in its Phase 2 CANAL trial for Haduvio, showing a 75.1% reduction in cough frequency in IPF patients, backed by statistically significant data. Trevi ended the quarter with approximately $126 million in cash and equivalents, poised to fund further development.
Trevi Therapeutics (Nasdaq: TRVI) announced participation in the Stifel 2022 Healthcare Conference on November 16, 2022, from 3:35 p.m. to 4:05 p.m. EDT. CEO Jennifer Good and CFO Lisa Delfini will be present for a fireside chat discussing their investigational therapy Haduvio™ for chronic cough. A live audio webcast will be available on their website, with an archive accessible post-event. Trevi focuses on developing Haduvio, which has shown positive results in Phase 2 trials for chronic cough associated with idiopathic pulmonary fibrosis (IPF).
Trevi Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on November 10, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results and provide a corporate update. The focus will be on its investigational therapy, Haduvio, for chronic cough conditions. The company has completed a Phase 2 trial for Haduvio's efficacy in treating chronic cough linked to idiopathic pulmonary fibrosis (IPF) and aims to target further development in chronic cough conditions including IPF and refractory chronic cough.
Trevi Therapeutics (Nasdaq: TRVI) announced statistically significant data from its Phase 2 CANAL trial of Haduvio (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF). The trial demonstrated a 76.1% reduction in 24-hour cough frequency for nalbuphine ER subjects versus 25.3% for placebo (p0.0001). Key secondary endpoints also showed significant improvement. The results will be presented at the British Thoracic Society's Winter Meeting in London on November 23, 2022. Chronic cough affects over a million patients globally, highlighting the importance of effective treatments.
Summary not available.